MARKET

ZYNE

ZYNE

Zynerba Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.490
+0.030
+0.67%
After Hours: 4.500 +0.01 +0.22% 18:03 05/17 EDT
OPEN
4.310
PREV CLOSE
4.460
HIGH
4.550
LOW
4.300
VOLUME
996.07K
TURNOVER
--
52 WEEK HIGH
9.00
52 WEEK LOW
3.120
MARKET CAP
185.22M
P/E (TTM)
-2.3099
1D
5D
1M
3M
1Y
5Y
Zynerba Pharmaceuticals Announces Podium and Poster Presentations at the International Society for Pharmacoeconomic and Outcomes Research (ISPOR) Virtual 2021 Conference
DEVON, Pa., May 17, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced an oral podiu...
GlobeNewswire · 10h ago
The Week In Cannabis: Trulieve's $2.1B Acquisition, New ETF, Earnings, Federal Legalization And More
In a week of big M&A news and mixed earnings reports, cannabis stocks traded mostly down.
Benzinga · 3d ago
A Complete List Of NYSE And NASDAQ-Listed Cannabis Companies
As the cannabis industry keeps pushing forward, more companies are moving to list their stock on a major U.S. exchange like the NYSE or NASDAQ. The club, however, remains relatively small.
Benzinga · 3d ago
Proactive news headlines including Ion Energy, Altamira Gold, BioHarvest Sciences and Melkior Resources
New York, May 12, May 12, 2021 (GLOBE NEWSWIRE via COMTEX) -- New York, May 12, 2021 (GLOBE NEWSWIRE) -- Proactive, provider of real-time news and video...
GlobeNewswire · 5d ago
Zynerba's Shares Jump on CBD Zygel Trial Plans, Company Reports Cash Until 2024
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) disclosed Wednesday its first-quarter net loss of $8.0 million or a loss of 20 cents per share, compared to $12.34 million in the same period of 2020 or a loss of 53 cents per share. First Quarter Highlights
Benzinga · 5d ago
10-Q: ZYNERBA PHARMACEUTICALS, INC.
(EDGAR Online via COMTEX) -- Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations You should read the following...
Edgar Online - (EDG = 10Q, 10K) · 5d ago
8-K: Zynerba Pharmaceuticals, Inc.
(EDGAR Online via COMTEX) -- 0001621443 false 0001621443 2021-05-12 2021-05-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 5d ago
Zynerba Pharmaceuticals EPS beats by $0.05
Zynerba Pharmaceuticals (ZYNE): Q1 GAAP EPS of -$0.20 beats by $0.05.Cash and cash equivalents of $93.1M as of March 31, 2021.Management believes that the Company’s cash and cash equivalents as of
Seekingalpha · 5d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ZYNE. Analyze the recent business situations of Zynerba Pharms through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ZYNE stock price target is 7.63 with a high estimate of 9.00 and a low estimate of 4.500.
EPS
Institutional Holdings
Institutions: 118
Institutional Holdings: 8.22M
% Owned: 19.94%
Shares Outstanding: 41.25M
TypeInstitutionsShares
Increased
13
2.19M
New
5
1.86K
Decreased
10
456.45K
Sold Out
6
254.62K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.79%
Pharmaceuticals & Medical Research
+0.65%
Key Executives
Chairman/Chief Executive Officer/Director
Armando Anido
President
Terri Sebree
Chief Financial Officer/Vice President
James Fickenscher
Vice President/General Counsel/Secretary
Suzanne Hanlon
Vice President/Director of Investor Relations
William Roberts
Vice President
Brian Rosenberger
Lead Director/Independent Director
Warren Cooper
Independent Director
John Butler
Independent Director
William Federici
Other
Liza Squires
Independent Director
Daniel Kisner
Independent Director
Kenneth Moch
Independent Director
Pamela Stephenson
No Data
  • All
  • Financials
  • Insiders
More
About ZYNE
Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is engaged in developing and commercializing transdermal synthetic cannabinoid treatments for patients with high unmet needs. Its development pipeline includes two product candidates: ZYN002 and ZYN001. ZYN002 is a synthetic cannabidiol (CBD), which is a non-psychoactive cannabinoid, formulated as a patent-protected permeation-enhanced gel for transdermal delivery through the skin and into the circulatory system. ZYN002 is in Phase II clinical development in patients with refractory epilepsy, in patients with osteoarthritis of the knee, as well as in patients with Fragile X syndrome. ZYN001 is a pro-drug of tetrahydrocannabinol (THC) that enables transdermal delivery through the skin and into the circulatory system through a patch. ZYN001 is targeting two pain indications, fibromyalgia and peripheral neuropathic pain.

Webull offers kinds of Zynerba Pharmaceuticals Inc stock information, including NASDAQ:ZYNE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ZYNE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ZYNE stock methods without spending real money on the virtual paper trading platform.